Genzyme Corp Drug Patent Portfolio
Genzyme Corp owns 2 orange book drugs protected by 11 US patents Given below is the list of Genzyme Corp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10888544 | Methods for treating Gaucher disease | 13 Dec, 2038 | Active |
| US10888547 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | 31 Jan, 2031 | Active |
| US11458119 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | 24 Nov, 2030 | Active |
| US8067427 | Pharmaceutical compositions comprising ZD6474 | 08 Aug, 2028 | Active |
| US7196205 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | 26 Jun, 2026 | Active |
| US6916802 | Amino ceramide-like compounds and therapeutic methods of use | 29 Apr, 2022 | Expired |
| US7253185 | Amino ceramide-like compounds and therapeutic methods of use | 29 Apr, 2022 | Expired |
| US7615573 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | 29 Apr, 2022 | Expired |
| US8642608 | Quinazoline derivatives as VEGF inhibitors | 06 Feb, 2022 | Expired |
| US7173038 | Quinazoline derivatives as VEGF inhibitors | 14 Aug, 2021 | Expired |
| USRE42353 | Quinazoline derivatives and pharmaceutical compositions containing them | 23 Sep, 2017 | Expired |
Latest Legal Activities on Genzyme Corp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Genzyme Corp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888547 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888544 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 May, 2023 | US8067427 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Oct, 2022 | US11458119 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Oct, 2022 | US11458119 |
|
Email Notification
Critical
| 15 Sep, 2022 | US11458119 |
|
Issue Notification Mailed
Critical
| 14 Sep, 2022 | US11458119 |
|
Email Notification
Critical
| 29 Jul, 2022 | US11458119 |
| Mailing Corrected Notice of Allowability | 29 Jul, 2022 | US11458119 |
| Dispatch to FDC | 28 Jul, 2022 | US11458119 |
|
Application Is Considered Ready for Issue
Critical
| 28 Jul, 2022 | US11458119 |
| Corrected Notice of Allowability | 26 Jul, 2022 | US11458119 |
|
Information Disclosure Statement considered
Critical
| 26 Jul, 2022 | US11458119 |
|
Pubs Case Remand to TC
Critical
| 15 Jul, 2022 | US11458119 |
|
Issue Fee Payment Verified
Critical
| 14 Jul, 2022 | US11458119 |
Genzyme Corp's Drug Patent Litigations
Genzyme Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 2019, against patent number US10888547. The petitioner , challenged the validity of this patent, with Genzyme Corporation as the respondent. Click below to track the latest information on how companies are challenging Genzyme Corp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11458119 | November, 2020 |
Decision
(27 Sep, 2021)
| Hanlan Liu et al. | |
| US10888547 | April, 2019 |
Decision
(30 Apr, 2020)
| Genzyme Corporation | |
Genzyme Corp Drug Patents' Oppositions Filed in EPO
Genzyme Corp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2015, by Sandoz Ag. This opposition was filed on patent number EP10785289A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16175117A | May, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP16175117A | May, 2020 | Hetero Labs Limited | Granted and Under Opposition |
| EP16175117A | May, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10785289A | Feb, 2015 | SANDOZ AG | Patent maintained as amended |
Genzyme Corp's Family Patents
Genzyme Corp Drug List
Given below is the complete list of Genzyme Corp's drugs and the patents protecting them.
1. Caprelsa
Caprelsa is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8067427 | Pharmaceutical compositions comprising ZD6474 |
08 Aug, 2028
(3 years from now)
| Active |
| US8642608 | Quinazoline derivatives as VEGF inhibitors |
06 Feb, 2022
(3 years ago)
| Expired |
| US7173038 | Quinazoline derivatives as VEGF inhibitors |
14 Aug, 2021
(3 years ago)
| Expired |
| USRE42353 | Quinazoline derivatives and pharmaceutical compositions containing them |
23 Sep, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caprelsa's drug page
2. Cerdelga
Cerdelga is protected by 7 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10888544 | Methods for treating Gaucher disease |
13 Dec, 2038
(13 years from now)
| Active |
| US10888547 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
31 Jan, 2031
(5 years from now)
| Active |
| US11458119 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
24 Nov, 2030
(5 years from now)
| Active |
| US7196205 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
26 Jun, 2026
(1 year, 25 days from now)
| Active |
| US6916802 | Amino ceramide-like compounds and therapeutic methods of use |
29 Apr, 2022
(3 years ago)
| Expired |
| US7253185 | Amino ceramide-like compounds and therapeutic methods of use |
29 Apr, 2022
(3 years ago)
| Expired |
| US7615573 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
29 Apr, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cerdelga's drug page